Earnings Releases·Nov 12, 2026, 4:01 PM ET

Arrowhead Pharmaceuticals — 2026 Fiscal Year-End Earnings Summary

Revenue declined 46% year-over-year to $450.8 million in 2026 from $829.4 million in 2025, while operating expenses surged to $1.16 billion from $731.1 million, driven by a $215.0 million acquisition of a Priority Review Voucher and increased R&D and SG&A costs.
The company reported a net loss of $724.2 million ($5.11 per share) in 2026 compared to a net loss of $1.6 million ($0.01 per share) in 2025, though total cash resources increased to $1.19 billion as available-for-sale securities rose to $1.13 billion.
Strategic financing included refinancing a credit facility to a $400 million senior secured term loan at SOFR plus 5.50% and acquiring a Priority Review Voucher to expedite regulatory review for the sHTG indication of plozasiran.
Commercial momentum for REDEMPLO (plozasiran) in FCS showed 63% quarter-over-quarter growth in new-to-brand prescriptions, while Phase 3 sHTG trials (SHASTA-3 and SHASTA-4) met primary endpoints with triglyceride reductions of 79% and 81%.
Future outlook targets a potential U.S. launch for plozasiran in sHTG in Q2 2027 pending approval, with the YOSEMITE Phase 3 trial for zodasiran expected to complete in mid-2027, alongside a fiscal year-end change from September 30 to December 31 effective January 1, 2027.